In an elderly woman (≥ 80 years) with dementia residing in a nursing home who has a valproic acid (VPA) trough level of 38 µg/mL, what is the appropriate management—should the dose be increased, maintained, or discontinued?

Management of Valproic Acid Level of 38 µg/mL in an Elderly Nursing Home Resident with Dementia

Discontinue Valproic Acid Immediately

Valproic acid should be discontinued in this patient because the level of 38 µg/mL is subtherapeutic, the evidence for efficacy in dementia-related agitation is weak at best, and elderly nursing home residents with dementia face substantially elevated risks of adverse effects without proven benefit. 1, 2

---

Why Discontinuation Is the Correct Decision

Subtherapeutic Level Without Demonstrated Benefit

• The current valproic acid level of 38 µg/mL falls well below the therapeutic range of 50–100 µg/mL established for epilepsy, and even below the 40–60 µg/mL range suggested by some uncontrolled dementia trials. 1, 2
• Placebo-controlled trials of valproic acid for agitation in dementia have shown no significant behavioral improvements at similar or higher serum levels, while uncontrolled case series reported modest benefits only at levels of 40–60 µg/mL. 2
• The evidence base consists primarily of small, uncontrolled case series; the few randomized controlled trials found valproic acid no better than placebo for agitation in dementia. 3, 4, 2

High-Risk Population Excluded from Evidence Base

• Large randomized trials of behavioral interventions and medications in dementia explicitly excluded nursing home residents, meaning there is no high-quality evidence supporting valproic acid use in this exact population. 5
• Elderly patients (especially those over 80 years) are more susceptible to neuropsychiatric complications from valproic acid, including myoclonus, somnolence, tremor, and cognitive worsening. 1, 6, 7
• The FDA label mandates that elderly patients require lower starting doses, slower titration, and close monitoring for somnolence, dehydration, and nutritional intake—none of which justify continuing a subtherapeutic, ineffective medication. 1

Safer and More Effective Alternatives Exist

• SSRIs (citalopram 10–40 mg/day or sertraline 25–200 mg/day) are the evidence-based first-line pharmacologic treatment for chronic agitation in dementia, with demonstrated efficacy in reducing neuropsychiatric symptoms and a far superior safety profile compared to valproic acid. 8
• Non-pharmacological interventions—environmental modifications, structured routines, caregiver education, pain management, and treatment of reversible medical causes (infections, constipation, dehydration)—must be prioritized before any medication. 8
• If severe acute agitation with imminent risk of harm occurs despite behavioral interventions, low-dose haloperidol (0.5–1 mg, maximum 5 mg/24 h) or risperidone (0.25–1.25 mg/day) are preferred over valproic acid for short-term crisis management. 8

---

Practical Tapering Protocol

Gradual Discontinuation Over 2–4 Weeks

• Taper valproic acid gradually over 2–4 weeks to avoid withdrawal seizures (though this patient has dementia, not epilepsy, so seizure risk is minimal). 8
• Example taper schedule for a patient on 500 mg/day: reduce to 375 mg/day for 1 week, then 250 mg/day for 1 week, then 125 mg/day for 1 week, then discontinue. 1
• Monitor closely for any resurgence of behavioral symptoms during the taper; if agitation worsens, address with non-pharmacological interventions first, then consider an SSRI rather than re-escalating valproic acid. 8

Concurrent Optimization of Non-Pharmacological Strategies

• While tapering valproic acid, intensify behavioral interventions: ensure adequate lighting (especially in late afternoon to prevent sundowning), reduce excessive noise, establish predictable daily routines, use calm tones with simple one-step commands, and provide at least 30 minutes of daily sunlight exposure. 8
• Systematically investigate and treat reversible medical contributors: pain (a major driver of agitation in non-communicative patients), urinary tract infections, pneumonia, constipation, urinary retention, dehydration, and metabolic disturbances. 8
• Review all medications to identify and discontinue anticholinergic agents (diphenhydramine, oxybutynin, cyclobenzaprine) that worsen confusion and agitation. 8

---

If Behavioral Symptoms Persist After Valproic Acid Discontinuation

Initiate an SSRI as First-Line Pharmacologic Treatment

• Citalopram: start 10 mg/day, increase to 20 mg/day after 1 week if tolerated, maximum 40 mg/day. 8
• Sertraline: start 25–50 mg/day, titrate by 25–50 mg increments weekly, maximum 200 mg/day. 8
• Assess response after 4 weeks of adequate dosing using a quantitative measure (Cohen-Mansfield Agitation Inventory or NPI-Q); if no clinically meaningful benefit, taper and discontinue the SSRI. 8

Reserve Antipsychotics for Severe, Dangerous Agitation Only

• Antipsychotics (haloperidol 0.5–1 mg or risperidone 0.25–0.5 mg) should be used only when the patient is severely agitated, distressed, or threatening substantial harm to self or others, and only after behavioral interventions and SSRIs have failed. 8
• All antipsychotics increase mortality risk by 1.6–1.7 times in elderly dementia patients; this risk must be discussed with the surrogate decision-maker before initiation. 8
• Use the lowest effective dose for the shortest possible duration (ideally <3–6 months), with daily in-person evaluation and monitoring for extrapyramidal symptoms, falls, QT prolongation, and metabolic changes. 8

---

Common Pitfalls to Avoid

• Do not increase the valproic acid dose in an attempt to reach "therapeutic" levels; the evidence does not support efficacy even at higher levels, and adverse effects increase substantially with dose escalation. 2
• Do not continue valproic acid indefinitely simply because "it's been working"—there is no evidence it provides benefit at subtherapeutic levels, and the risks (somnolence, tremor, cognitive decline, thrombocytopenia, hepatotoxicity) outweigh any theoretical benefit. 1, 2
• Do not add an antipsychotic on top of valproic acid without first discontinuing valproic acid and optimizing non-pharmacological interventions; polypharmacy in this population dramatically increases fall risk, sedation, and mortality. 8
• Do not overlook reversible medical causes (pain, infection, constipation, dehydration) that are far more likely to be driving behavioral symptoms than any medication deficiency. 8

---

Summary Algorithm

1. Discontinue valproic acid gradually over 2–4 weeks. 1
2. Intensify non-pharmacological interventions (environmental modifications, caregiver education, structured routines, pain management, treatment of infections/constipation/dehydration). 8
3. If agitation persists after 4 weeks, initiate an SSRI (citalopram 10–40 mg/day or sertraline 25–200 mg/day). 8
4. Reassess after 4 weeks of adequate SSRI dosing; if no benefit, taper and discontinue. 8
5. Reserve antipsychotics (haloperidol 0.5–1 mg or risperidone 0.25–0.5 mg) for severe, dangerous agitation only, after documented failure of behavioral interventions and SSRIs. 8
6. Monitor closely for adverse effects (falls, sedation, extrapyramidal symptoms, QT prolongation) and attempt taper within 3–6 months if antipsychotics are used. 8